Tag: Gilead

3 Reasons Gilead Sciences Jumped to Buy Kite Pharma

Gilead Sciences Inc. (NASDAQ:GILD) might be the most disciplined capital allocator in biotech. For years, its management has resisted calls from the peanut gallery to make a big acquisition, while it built a fortress balance sheet that boasted $ 36.6 billion cash and equivalents at the end of June.   Gilead cited an overpriced market…